$EVFM
Evofem Biosciences, Inc.

2023 Q4 Form 10-Q Financial Statement

#000149315223040764 Filed on November 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $100.0M $5.112M
YoY Change 55148.62% -19.76%
Cost Of Revenue $954.0K $1.889M
YoY Change 148.44% 12.44%
Gross Profit $3.885M $3.223M
YoY Change -2013.79% -31.29%
Gross Profit Margin 3.89% 63.05%
Selling, General & Admin $5.882M $6.161M
YoY Change -42.1% -66.16%
% of Gross Profit 151.4% 191.16%
Research & Development $1.383M $614.0K
YoY Change -18.17% -88.21%
% of Gross Profit 35.6% 19.05%
Depreciation & Amortization $22.00K $37.00K
YoY Change -91.2% -85.2%
% of Gross Profit 0.57% 1.15%
Operating Expenses $7.265M $6.775M
YoY Change -38.69% -71.07%
Operating Profit -$3.380M -$3.552M
YoY Change -71.95% -81.03%
Interest Expense $1.853M -$5.173M
YoY Change -58.72% -104.76%
% of Operating Profit
Other Income/Expense, Net -$587.0K $69.57M
YoY Change -23.27% -35.73%
Pretax Income -$2.114M $66.02M
YoY Change -74.62% -26.25%
Income Tax $0.00 $11.00K
% Of Pretax Income 0.02%
Net Earnings -$5.098M $66.01M
YoY Change -55.59% -26.26%
Net Earnings / Revenue -5.1% 1291.18%
Basic Earnings Per Share $15.34
Diluted Earnings Per Share -$0.43 $0.10
COMMON SHARES
Basic Shares Outstanding 10.73M shares 4.060M shares
Diluted Shares Outstanding 730.0M shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $0.00 $0.00
YoY Change -100.0% -100.0%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets $1.775M $2.657M
YoY Change -48.18% -56.45%
Inventory $1.697M $2.526M
Prepaid Expenses
Receivables $5.738M $6.322M
Other Receivables $0.00 $0.00
Total Short-Term Assets $9.210M $11.51M
YoY Change -27.47% -63.81%
LONG-TERM ASSETS
Property, Plant & Equipment $1.203M $1.631M
YoY Change -69.47% -61.86%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $35.00K $35.00K
YoY Change -99.15% -96.85%
Total Long-Term Assets $1.344M $1.817M
YoY Change -89.22% -82.68%
TOTAL ASSETS
Total Short-Term Assets $9.210M $11.51M
Total Long-Term Assets $1.344M $1.817M
Total Assets $10.55M $13.32M
YoY Change -58.06% -68.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $17.02M $16.20M
YoY Change 13.59% 11.39%
Accrued Expenses $4.227M $5.100M
YoY Change 2.5% -7.36%
Deferred Revenue $3.200M
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $43.27M $41.08M
YoY Change -34.13% -47.01%
Total Short-Term Liabilities $72.46M $67.87M
YoY Change -22.77% -41.85%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $8.000K $12.43K
YoY Change -99.74%
Total Long-Term Liabilities $8.000K $12.43K
YoY Change -99.74%
TOTAL LIABILITIES
Total Short-Term Liabilities $72.46M $67.87M
Total Long-Term Liabilities $8.000K $12.43K
Total Liabilities $72.47M $67.88M
YoY Change -25.26% -43.59%
SHAREHOLDERS EQUITY
Retained Earnings -$888.7M -$884.6M
YoY Change -5.33% -4.92%
Common Stock $2.000K $0.00
YoY Change -100.0% -100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$66.51M -$56.36M
YoY Change
Total Liabilities & Shareholders Equity $10.55M $13.32M
YoY Change -58.06% -68.49%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$5.098M $66.01M
YoY Change -55.59% -26.26%
Depreciation, Depletion And Amortization $22.00K $37.00K
YoY Change -91.2% -85.2%
Cash From Operating Activities -$170.0K -$2.364M
YoY Change -97.4% -85.5%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0% -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 340.0K 2.138M
YoY Change -77.33% -45.82%
NET CHANGE
Cash From Operating Activities -170.0K -2.364M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 340.0K 2.138M
Net Change In Cash 170.0K -226.0K
YoY Change -103.36% -98.18%
FREE CASH FLOW
Cash From Operating Activities -$170.0K -$2.364M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$170.0K -$2.364M
YoY Change -97.41% -85.43%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
dei Entity Central Index Key
EntityCentralIndexKey
0001618835
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
usd
CY2023Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
usd
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
usd
CY2022Q3 EVFM Gain Loss On Issuance Of Financial Instruments
GainLossOnIssuanceOfFinancialInstruments
usd
CY2023Q3 us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
usd
CY2023Q3 EVFM Temporary Equity Convertible Preferred Stock Deemed Dividends
TemporaryEquityConvertiblePreferredStockDeemedDividends
usd
CY2022Q3 EVFM Temporary Equity Convertible Preferred Stock Deemed Dividends
TemporaryEquityConvertiblePreferredStockDeemedDividends
usd
EVFM Temporary Equity Convertible Preferred Stock Deemed Dividends
TemporaryEquityConvertiblePreferredStockDeemedDividends
usd
CY2022Q3 us-gaap Extinguishment Of Debt Amount
ExtinguishmentOfDebtAmount
usd
us-gaap Extinguishment Of Debt Amount
ExtinguishmentOfDebtAmount
usd
CY2023Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
usd
CY2023Q3 us-gaap Warrant Down Round Feature Increase Decrease In Equity Amount1
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
usd
CY2022Q1 EVFM Exchange Of Series B2 Convertible Preferred Stock Value
ExchangeOfSeriesB2ConvertiblePreferredStockValue
usd
CY2022Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
usd
CY2022Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
usd
CY2022Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
usd
us-gaap Inventory Write Down
InventoryWriteDown
usd
EVFM Financial Instrument Modification Expense
FinancialInstrumentModificationExpense
usd
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
usd
EVFM Financial Instrument Expense Noncash
FinancialInstrumentExpenseNoncash
usd
EVFM Proceeds From Issuance Of Common Stock Stock Purchase Agreement
ProceedsFromIssuanceOfCommonStockStockPurchaseAgreement
usd
EVFM Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
usd
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
usd
EVFM Borrowings Under Term Notes Included In Prepaid And Other Current Assets
BorrowingsUnderTermNotesIncludedInPrepaidAndOtherCurrentAssets
usd
EVFM Financing Costs Included In Accounts Payable And Accrued Expenses
FinancingCostsIncludedInAccountsPayableAndAccruedExpenses
usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
usd
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
usd
EVFM Exchange Of Series B2 Convertible Preferred Stock To Series C Convertible Preferred Stock
ExchangeOfSeriesB2ConvertiblePreferredStockToSeriesCConvertiblePreferredStock
usd
us-gaap Stock Issued1
StockIssued1
usd
EVFM Exchange Of Adjuvant Notes To Purchase Rights
ExchangeOfAdjuvantNotesToPurchaseRights
usd
EVFM Exchange Of Term Notes To Purchase Rights
ExchangeOfTermNotesToPurchaseRights
usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
usd
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
usd
CY2023Q3 EVFM Derivative Liability Change In Fair Value
DerivativeLiabilityChangeInFairValue
usd
CY2022Q3 EVFM Purchase Rights Change In Fair Value
PurchaseRightsChangeInFairValue
usd
CY2023Q3 EVFM Gains Loss On Extinguishment Of Debt
GainsLossOnExtinguishmentOfDebt
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36754
dei Entity Registrant Name
EntityRegistrantName
EVOFEM BIOSCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-8527075
dei Entity Address Address Line1
EntityAddressAddressLine1
7770 Regents Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 113-618
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92122
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92122
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
550-1900
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
EVFM
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10730210 shares
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2769000 usd
CY2023Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
410000 usd
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
1207000 usd
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6322000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1126000 usd
CY2023Q3 us-gaap Inventory Net
InventoryNet
2526000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
5379000 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2247000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2218000 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
11505000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
12699000 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1631000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3940000 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
151000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4406000 usd
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
35000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4118000 usd
CY2023Q3 us-gaap Assets
Assets
13322000 usd
CY2022Q4 us-gaap Assets
Assets
25163000 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
16199000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
14984000 usd
CY2023Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
13110000 usd
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
39416000 usd
CY2023Q3 EVFM Convertible Notes Payable Current Adjuvant
ConvertibleNotesPayableCurrentAdjuvant
27969000 usd
CY2022Q4 EVFM Convertible Notes Payable Current Adjuvant
ConvertibleNotesPayableCurrentAdjuvant
26268000 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5100000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4124000 usd
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1820000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2175000 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
138000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2311000 usd
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1676000 usd
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3532000 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2876000 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
67868000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
93830000 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
13000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3133000 usd
CY2023Q3 us-gaap Liabilities
Liabilities
67881000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
96963000 usd
CY2023Q3 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0 shares
CY2023Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0 shares
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2023Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
1800000 usd
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3000000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3000000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5680210 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5680210 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
984786 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
984786 shares
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
828552000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
817367000 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-287000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
49527000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-884624000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-938694000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-56359000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-71800000 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13322000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25163000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5112000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6371000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
13379000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16656000 usd
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1889000 usd
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1680000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5558000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4031000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
614000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5207000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1556000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23342000 usd
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2985000 usd
CY2022Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
11948000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
9036000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
36951000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3176000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6260000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11696000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24404000 usd
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
8664000 usd
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
25095000 usd
us-gaap Costs And Expenses
CostsAndExpenses
27846000 usd
us-gaap Costs And Expenses
CostsAndExpenses
88728000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3552000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-18724000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-14467000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-72072000 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
2000 usd
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
50000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
28000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
55000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-596000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-436000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2041000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1322000 usd
CY2023Q3 EVFM Gain Loss On Issuance Of Financial Instruments
GainLossOnIssuanceOfFinancialInstruments
5175000 usd
EVFM Gain Loss On Issuance Of Financial Instruments
GainLossOnIssuanceOfFinancialInstruments
5286000 usd
EVFM Gain Loss On Issuance Of Financial Instruments
GainLossOnIssuanceOfFinancialInstruments
72002000 usd
CY2023Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
75337000 usd
CY2022Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-24487000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
75337000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-24487000 usd
CY2022Q3 us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
133116000 usd
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
1539000 usd
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
101502000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
69568000 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
108243000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
69577000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3746000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
66016000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
89519000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
55110000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-68326000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
11000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
17000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
36000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
66005000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
89506000 usd
us-gaap Net Income Loss
NetIncomeLoss
55093000 usd
us-gaap Net Income Loss
NetIncomeLoss
-68362000 usd
EVFM Temporary Equity Convertible Preferred Stock Deemed Dividends
TemporaryEquityConvertiblePreferredStockDeemedDividends
-1827000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
66005000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
89506000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
55093000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-66535000 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
15.34
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
135.72
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
21.42
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-206.38
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.10
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.39
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-206.38
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4236477 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
659480 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2524302 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
322385 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
729979486 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4441972 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
694561898 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
322385 shares
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
66005000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
89506000 usd
us-gaap Net Income Loss
NetIncomeLoss
55093000 usd
us-gaap Net Income Loss
NetIncomeLoss
-68362000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment
-455000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment
35362000 usd
us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment
23373000 usd
us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment
31868000 usd
CY2023Q3 us-gaap Extinguishment Of Debt Amount
ExtinguishmentOfDebtAmount
73187000 usd
us-gaap Extinguishment Of Debt Amount
ExtinguishmentOfDebtAmount
73187000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7637000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
124868000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
5279000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36494000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-71800000 usd
CY2023Q1 EVFM Stock Issued During Period Value Common Stock Upon Cash Exercise Of Warrants
StockIssuedDuringPeriodValueCommonStockUponCashExerciseOfWarrants
67000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
1629000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
417000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment
15460000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2354000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-56401000 usd
CY2023Q2 EVFM Stock Issued During Period Value Common Stock Upon Cash Exercise Of Warrants
StockIssuedDuringPeriodValueCommonStockUponCashExerciseOfWarrants
101000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
53000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments
499000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
268000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment
8368000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-8558000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-55664000 usd
CY2023Q3 EVFM Stock Issued During Period Value Common Stock Upon Cash Exercise Of Warrants
StockIssuedDuringPeriodValueCommonStockUponCashExerciseOfWarrants
14000 usd
CY2023Q3 EVFM Issuance Of Series E1 Convertible And Redeemable Preferred Stock Upon Exchange Of Notes
IssuanceOfSeriesE1ConvertibleAndRedeemablePreferredStockUponExchangeOfNotes
-1800000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments
3563000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
4904000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
258000 usd
CY2023Q3 us-gaap Extinguishment Of Debt Amount
ExtinguishmentOfDebtAmount
73187000 usd
CY2023Q3 EVFM Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustments
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustments
-452000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
66005000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-56359000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-104315000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
5400000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
708000 usd
CY2022Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
81000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment
181000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
828000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1067000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-31888000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-128100000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
2553000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
1264000 usd
CY2022Q2 EVFM Stock Issued During Period Value Common Stock Upon Cash Exercise Of Warrants
StockIssuedDuringPeriodValueCommonStockUponCashExerciseOfWarrants
32889000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
20000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
858000 usd
CY2022Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
18000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
543000 usd
CY2022Q2 EVFM Stock Issued During Period Value Exchange Transaction
StockIssuedDuringPeriodValueExchangeTransaction
2339000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment
-3675000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
231000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1081000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-125980000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-215995000 usd
CY2022Q3 EVFM Stock Issued During Period Value Common Stock Upon Cash Exercise Of Warrants
StockIssuedDuringPeriodValueCommonStockUponCashExerciseOfWarrants
9043000 usd
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
523000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
2550000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
-25000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment
OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment
35362000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
11000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
981000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
89506000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-78044000 usd
us-gaap Net Income Loss
NetIncomeLoss
55093000 usd
us-gaap Net Income Loss
NetIncomeLoss
-68362000 usd
EVFM Gain Loss On Issuance Of Financial Instruments
GainLossOnIssuanceOfFinancialInstruments
5286000 usd
EVFM Gain Loss On Issuance Of Financial Instruments
GainLossOnIssuanceOfFinancialInstruments
72002000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
75337000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-24487000 usd
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
1539000 usd
us-gaap Fair Value Option Changes In Fair Value Gain Loss1
FairValueOptionChangesInFairValueGainLoss1
101502000 usd
us-gaap Inventory Write Down
InventoryWriteDown
1505000 usd
EVFM Financial Instrument Modification Expense
FinancialInstrumentModificationExpense
1067000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
943000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
3130000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
455000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
765000 usd
us-gaap Interest Expense
InterestExpense
1702000 usd
us-gaap Interest Expense
InterestExpense
1605000 usd
us-gaap Lease Cost
LeaseCost
1259000 usd
us-gaap Lease Cost
LeaseCost
34000 usd
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
466000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-1858000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-926000 usd
EVFM Financial Instrument Expense Noncash
FinancialInstrumentExpenseNoncash
514000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5196000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
6314000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1348000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-2495000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3231000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1981000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1215000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4044000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1632000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-650000 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-355000 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
176000 usd
EVFM Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
1432000 usd
EVFM Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
277000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8798000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-63879000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
306000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-306000 usd
EVFM Proceeds From Issuance Of Common Stock Stock Purchase Agreement
ProceedsFromIssuanceOfCommonStockStockPurchaseAgreement
7438000 usd
EVFM Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
24882000 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
174000 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
25211000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
20000 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
5262000 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
10000000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1000000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
5892000 usd
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
1202000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
18000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4436000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
60439000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4366000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3746000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4776000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13588000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
410000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
9842000 usd
EVFM Exchange Of Convertible Notes To Series E1 Convertible Preferred Stock
ExchangeOfConvertibleNotesToSeriesE1ConvertiblePreferredStock
1800000 usd
EVFM Borrowings Under Term Notes Included In Prepaid And Other Current Assets
BorrowingsUnderTermNotesIncludedInPrepaidAndOtherCurrentAssets
375000 usd
EVFM Issuance Of Common Stock Upon Exercise Of Purchase Rights
IssuanceOfCommonStockUponExerciseOfPurchaseRights
186000 usd
EVFM Issuance Of Common Stock Upon Exercise Of Purchase Rights
IssuanceOfCommonStockUponExerciseOfPurchaseRights
522000 usd
EVFM Financing Costs Included In Accounts Payable And Accrued Expenses
FinancingCostsIncludedInAccountsPayableAndAccruedExpenses
302000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
113000 usd
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
1187000 usd
EVFM Exchange Of Series B2 Convertible Preferred Stock To Series C Convertible Preferred Stock
ExchangeOfSeriesB2ConvertiblePreferredStockToSeriesCConvertiblePreferredStock
1616000 usd
us-gaap Stock Issued1
StockIssued1
3412000 usd
EVFM Exchange Of Adjuvant Notes To Purchase Rights
ExchangeOfAdjuvantNotesToPurchaseRights
634000 usd
EVFM Exchange Of Term Notes To Purchase Rights
ExchangeOfTermNotesToPurchaseRights
4806000 usd
CY2023Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
a reverse stock split between 1-for-20 and not more than 1-for-125 at any time on or prior to March 15, 2024. The Company decided on a ratio of 1-for-125 for the Reverse Stock Split. On May 18, 2023, the Reverse Stock Split became effective.
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
5300000 usd
CY2023Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
400000 usd
CY2023Q3 EVFM Working Capital Surplus Deficit
WorkingCapitalSurplusDeficit
56400000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-884600000 usd
CY2022Q4 us-gaap Share Price
SharePrice
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
EVFM Milestone Method Revenue Recognized
MilestoneMethodRevenueRecognized
100000000.0 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84C_eus-gaap--UseOfEstimates_zAU1tQZMM988" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_zcgEZ3OQgW12">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the notes thereto.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant estimates affecting amounts reported or disclosed in the condensed consolidated financial statements include, but are not limited to: the assumptions used in measuring the revenue gross-to-net variable consideration items; the trade accounts receivable credit loss reserve estimate; the discount rate used in estimating the fair value of the lease right<b>-</b>of<b>-</b>use (ROU) assets and lease liabilities; the assumptions used in estimating the fair value of convertible notes, warrants and purchase rights issued and modified; the useful lives of property and equipment; the recoverability of long-lived assets; clinical trial accruals; and the assumptions used in estimating the fair value of stock-based compensation expense. These assumptions are more fully described in <span style="text-decoration: underline">Note 3 – Revenue</span>, <span style="text-decoration: underline">Note 4 – Debt</span>, <span style="text-decoration: underline">Note 6 – Fair Value of Financial Instruments</span>, <span style="text-decoration: underline">Note 7 – Commitments and Contingencies</span> and <span style="text-decoration: underline">Note 9 – Stock-based Compensation</span>. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances and adjusts when facts and circumstances dictate. The estimates are the basis for making judgments about the carrying values of assets, liabilities and recorded expenses that are not readily apparent from other sources. As future events and their effects cannot be determined with precision, actual results may materially differ from those estimates or assumptions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_zUG3zgVxOwal" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_863_z7lrIbdLF8Q4">Concentrations of Credit Risk</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. Deposits in the Company’s checking and time deposit accounts are maintained in federally insured financial institutions and are subject to federally insured limits or limits set by the Securities Investor Protection Corporation. The Company holds its funds through a major U.S. bank and is exposed to credit risk in the event of default to the extent of amounts recorded on the condensed consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has not experienced any losses in such accounts and believes it is not exposed to significant concentrations of credit risk on its cash, cash equivalents and restricted cash balances on amounts in excess of federally insured limits due to the financial position of the depository institutions in which these deposits are held. The Company’s deposits were primarily held in Silicon Valley Bank prior to its closure by regulators, however, the Company was able to regain full access to all its deposits and subsequently moved these to a different financial institution.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is also subject to credit risk related to its trade accounts receivable from product sales. Its customers are located in the United States and consist of wholesale distributors, retail pharmacies, and a mail-order specialty pharmacy. The Company extends credit to its customers in the normal course of business after evaluating their overall financial condition and evaluates the collectability of its accounts receivable by periodically reviewing the age of the receivables, the financial condition of its customers and its past collection experience. Historically, the Company has not experienced any credit losses. As of September 30, 2023 and December 31, 2022, based on the evaluation of these factors, the Company did not record an allowance for doubtful accounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phexxi is distributed primarily through three major distributors and a mail-order pharmacy, which receive service fees calculated as a percentage of the gross sales, and fee per units shipped, respectively. These entities are not obligated to purchase any set number of units and distribute Phexxi on demand as orders are received. For the three and nine months ended September 30, 2023, the Company’s three largest customers combined made up approximately <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--ThreeLargestCustomersCombinedMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zEsn19TFtTW9">86</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% and <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--ThreeLargestCustomersCombinedMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z1IhIWmYgqqg">85</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% of its gross product sales, respectively. For the three and nine months ended September 30, 2022, the Company’s three largest customers combined made up approximately <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220701__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--ThreeLargestCustomersCombinedMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zyjkDWIzHnIe">93</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% and <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--ThreeLargestCustomersCombinedMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zbNKG9GfXJ96">81</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% of its gross product sales, respectively. As of September 30, 2023 the Company’s three largest customers combined made up <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--ThreeLargestCustomersCombinedMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z3SmjUde4Cle">91</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%, of its trade accounts receivable balance. As of December 31, 2022, the Company’s four largest customers combined made up<span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--FourthLargestCustomersCombinedMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zdprjjAXa3R3"> 81</span>% of its trade accounts receivable balance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
25000000.0 usd
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
1064000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
61165000 usd
us-gaap Weighted Average Basic Shares Outstanding Pro Forma
WeightedAverageBasicSharesOutstandingProForma
2524302 shares
EVFM Weighted Average Shares Used To Compute Net Loss Attributable To Common Stockholder Diluted
WeightedAverageSharesUsedToComputeNetLossAttributableToCommonStockholderDiluted
694561899 shares
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.09
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1560000 usd
CY2023Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
51000 usd
CY2022Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
25000 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7749000 usd
CY2023Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
410000 usd
CY2022Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
1293000 usd
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
800000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
410000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
9842000 usd
CY2023Q3 us-gaap Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount
WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount
1000000.0 usd
us-gaap Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount
WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount
1000000.0 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5093969 shares
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
66005000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
89506000 usd
CY2022Q3 EVFM Derivative Liability Change In Fair Value
DerivativeLiabilityChangeInFairValue
-106898000 usd
CY2023Q3 EVFM Purchase Rights Change In Fair Value
PurchaseRightsChangeInFairValue
4904000 usd
CY2023Q3 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
361000 usd
CY2022Q3 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
367000 usd
CY2022Q3 EVFM Gains Loss On Extinguishment Of Debt
GainsLossOnExtinguishmentOfDebt
-2483000 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
71270000 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-19508000 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4236477 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
659480 shares
CY2023Q3 EVFM Weighted Average Shares Used To Compute Net Loss Attributable To Common Stockholder Basic
WeightedAverageSharesUsedToComputeNetLossAttributableToCommonStockholderBasic
731128443 shares
CY2022Q3 EVFM Weighted Average Shares Used To Compute Net Loss Attributable To Common Stockholder Basic
WeightedAverageSharesUsedToComputeNetLossAttributableToCommonStockholderBasic
4441972 shares
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.10
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.39
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
55093000 usd
EVFM Purchase Rights Change In Fair Value
PurchaseRightsChangeInFairValue
5008000 usd
CY2021Q4 EVFM Purchase Agreement Threshold Amount Of Aggregate Gross Proceeds From Future Sale Of Equity Securities
PurchaseAgreementThresholdAmountOfAggregateGrossProceedsFromFutureSaleOfEquitySecurities
50000000 usd
EVFM Milestone Method Revenue Recognized
MilestoneMethodRevenueRecognized
100000000.0 usd
CY2023Q1 us-gaap Debt Instrument Periodic Payment
DebtInstrumentPeriodicPayment
92700000 usd
EVFM Milestone Method Revenue Recognized
MilestoneMethodRevenueRecognized
100000000.0 usd
CY2023Q3 EVFM Cumulative Net Sales
CumulativeNetSales
100000000 usd
CY2023Q3 EVFM Accrued Interest Agreement Percentage
AccruedInterestAgreementPercentage
0.10 pure
CY2023Q4 us-gaap Interest Revenue Expense Net
InterestRevenueExpenseNet
1000000.0 usd
CY2023Q3 us-gaap Long Term Debt Contingent Payment Of Principal Or Interest
LongTermDebtContingentPaymentOfPrincipalOrInterest
The cash payments will be determined based upon the quarterly global net revenue of Phexxi such that if the global net revenue is less than or equal to $5.0 million, the Company will pay 3%; if the global net revenue is over $5.0 million and less than or equal to $7.0 million, the Company will continue to pay 3% on net revenue up to $5.0 million and 4% on the net revenue over $5.0 million; and if the global net revenue is over $7.0 million, the Company will pay 3% on the net revenue up to $5.0 million, 4% on the net revenue over $5.0 million up to $7.0 million, and 5% on net revenue over $7.0 million. The cash payments will be payable beginning in the fourth quarter of 2023. Regardless of the percentage paid, the quarterly cash payment amounts, along with the $1.0 million upfront payment, will be deducted from the Repurchase Price as Applicable Reductions
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
75300000 usd
CY2023Q3 EVFM Revalued Amount Extinguishment Of Debt Amount
RevaluedAmountExtinguishmentOfDebtAmount
73200000 usd
CY2023Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
516000 usd
CY2022Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
525000 usd
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1520000 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
179000 usd
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
45000 usd
CY2023Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
567000 usd
CY2022Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
550000 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
1699000 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
1605000 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
10985000 usd
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
7140000 usd
us-gaap Debt Conversion Converted Instrument Warrants Or Options Issued1
DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
31133775 shares
CY2023Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
557000 usd
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
758000 usd
CY2023Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
1105000 usd
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
4142000 usd
CY2023Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
864000 usd
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1748000 usd
CY2023Q3 us-gaap Inventory Gross
InventoryGross
2526000 usd
CY2022Q4 us-gaap Inventory Gross
InventoryGross
6648000 usd
CY2023Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
200000 usd
CY2023Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
900000 usd
CY2023Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
1300000 usd
CY2022Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
1300000 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2247000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2218000 usd
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2795000 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7129000 usd
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1164000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3189000 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1631000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3940000 usd
CY2023Q3 EVFM Accrued Clinical Studies Current
AccruedClinicalStudiesCurrent
2497000 usd
CY2022Q4 EVFM Accrued Clinical Studies Current
AccruedClinicalStudiesCurrent
2574000 usd
CY2023Q3 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
1015000 usd
CY2022Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
674000 usd
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1588000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
876000 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5100000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4124000 usd
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
2612000 usd
CY2023Q3 EVFM Convertible Notes Payable Current Outstanding Balance Principal And Interest
ConvertibleNotesPayableCurrentOutstandingBalancePrincipalAndInterest
100000 usd
CY2023Q3 us-gaap Gain Or Loss On Sale Of Stock In Subsidiary
GainOrLossOnSaleOfStockInSubsidiary
300000 usd
EVFM Number Of Leased Vehicles
NumberOfLeasedVehicles
21 integer
CY2019Q4 EVFM Office Square Footage
OfficeSquareFootage
24474 sqft
CY2020Q2 EVFM Office Square Footage
OfficeSquareFootage
8816 sqft
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3300000 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4200000 usd
CY2023Q2 us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
200000 usd
CY2022Q2 EVFM Lessee Operating Sublease Rentable Area
LesseeOperatingSubleaseRentableArea
16637 sqft
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000 usd
CY2022Q2 us-gaap Operating Leases Of Lessor Contingent Rentals Basis Spread On Variable Rate
OperatingLeasesOfLessorContingentRentalsBasisSpreadOnVariableRate
0.035 pure
CY2023Q3 us-gaap Sublease Income
SubleaseIncome
0 usd
CY2022Q3 us-gaap Sublease Income
SubleaseIncome
300000 usd
us-gaap Sublease Income
SubleaseIncome
300000 usd
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
58000 usd
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
343000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
764000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
1522000 usd
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y11M12D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y8M4D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.12 pure
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.12 pure
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
47000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
109000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
9000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
165000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
14000 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
151000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
1470000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
1969000 usd
CY2023Q3 us-gaap Unrecorded Unconditional Purchase Obligation Purchases
UnrecordedUnconditionalPurchaseObligationPurchases
0 usd
us-gaap Unrecorded Unconditional Purchase Obligation Purchases
UnrecordedUnconditionalPurchaseObligationPurchases
0 usd
CY2022Q3 us-gaap Unrecorded Unconditional Purchase Obligation Purchases
UnrecordedUnconditionalPurchaseObligationPurchases
0 usd
us-gaap Unrecorded Unconditional Purchase Obligation Purchases
UnrecordedUnconditionalPurchaseObligationPurchases
0 usd
CY2023Q3 us-gaap Accounts Payable Trade Current And Noncurrent
AccountsPayableTradeCurrentAndNoncurrent
1500000 usd
CY2023Q3 EVFM Accounts Payable Trade90 Days Past Due Or More Percent
AccountsPayableTrade90DaysPastDueOrMorePercent
0.89 pure
CY2023Q3 EVFM Common Stock Reserved Upon Exercise Of Common Stock Warrants
CommonStockReservedUponExerciseOfCommonStockWarrants
32639382000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock
AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
1800000 usd
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3000000000 shares
CY2023Q3 EVFM Loss On Issuance Of Financial Instruments
LossOnIssuanceOfFinancialInstruments
4900000 usd
CY2023Q3 EVFM Common Stock Reserved Upon Exercise Of Common Stock Warrants
CommonStockReservedUponExerciseOfCommonStockWarrants
32639382000 shares
CY2023Q3 EVFM Common Stock Capital Share Reserved For Future Issuance
CommonStockCapitalShareReservedForFutureIssuance
288237667000 shares
CY2023Q3 us-gaap Convertible Preferred Stock Shares Reserved For Future Issuance
ConvertiblePreferredStockSharesReservedForFutureIssuance
428570789000 shares
CY2023Q3 us-gaap Preferred Stock Capital Shares Reserved For Future Issuance
PreferredStockCapitalSharesReservedForFutureIssuance
21621302000 shares
CY2023Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
771079793000 shares
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
258000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
981000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
943000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3129000 usd
CY2023Q4 us-gaap Revenues
Revenues
100000000 usd

Files In Submission

Name View Source Status
evfm-20230930_pre.xml Edgar Link unprocessable
evfm-20230930_cal.xml Edgar Link unprocessable
0001493152-23-040764-index-headers.html Edgar Link pending
0001493152-23-040764-index.html Edgar Link pending
0001493152-23-040764.txt Edgar Link pending
0001493152-23-040764-xbrl.zip Edgar Link pending
evfm-20230930.xsd Edgar Link pending
evfm-20230930_lab.xml Edgar Link unprocessable
ex10-11.htm Edgar Link pending
ex10-12.htm Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
evfm-20230930_def.xml Edgar Link unprocessable